A meta-analysis of randomized controlled trials found that GLP-1 receptor agonists significantly decreased ALT levels compared to placebo or other glucose-lowering agents
In the trial, for patients with preexisting cardiovascular disease and overweight or obesity but without diabetes, weekly injections of semaglutide at a dose of 2.4 mg was superior to placebo in reducing the risk of death from cardiovascular causes, nonfatal heart attack, or nonfatal stroke over an average follow-up of 40 months
Why women face higher UTI risk Anatomy drives much of the gender disparity in UTI rates
Saxenda is FDA-approved to help with chronic weight management in adults and children over the age of 12
External resources National Center for Biotechnology Information - Peptide Mechanisms Database Journal of Biological Chemistry - Signal Transduction Pathways In case I don't see you, good afternoon, good evening, and good night
Our Tampa office is at 3971 Moran Road, Suite 101, in Carrollwood (33618), just east of the Veterans Expressway